Pramlintide (Symlin)

Written by The Peptide Record editorialClinical review not yet completedLast reviewed 12 September 2026

Pramlintide is cagrilintide's approved ancestor — the same amylin-analog mechanism, but a drug that actually went through FDA approval in 2005 and stayed on the US market for two decades. The trial evidence behind it is real, if modest: meaningful A1c and weight reductions as an add-on to mealtime insulin, alongside a genuine, serious hypoglycemia risk. Its manufacturer discontinued it in late 2025 — not for a safety finding, but a real, recent wrinkle worth knowing if you're comparing it to this site's cagrilintide/CagriSema page.

In brief

Should you care? Yes if you've read this site's cagrilintide/CagriSema page — pramlintide is the same amylin-analog family, actually approved for two decades, and only just discontinued.

The short version

FDA-approved (Symlin, 16 March 2005) as adjunct to mealtime insulin in type 1 and type 2 diabetes.
Real 52-week randomized trial evidence backs modest A1c and weight benefits, in both type 1 and type 2 diabetes.
Discontinued by its manufacturer in late 2025 — a real, recent, commercial withdrawal, not a safety recall.

What it is

Pramlintide is a synthetic analog of amylin, a hormone co-secreted with insulin by pancreatic beta cells. It slows gastric emptying, suppresses inappropriate post-meal glucagon secretion, and promotes satiety via hypothalamic receptors. Amylin Pharmaceuticals developed it, and FDA approved it as Symlin on 16 March 2005, as an adjunct to mealtime insulin in adults with type 1 or type 2 diabetes not achieving adequate control on insulin alone.

The trial evidence

The key type 2 diabetes trial (Hollander et al., Diabetes Care 2003;26(3):784-790, PMID 12610038) randomized 656 insulin-using patients to one of three pramlintide doses or placebo for 52 weeks, finding a greater decline in HbA1c and body weight with pramlintide. In type 1 diabetes, Whitehouse et al. (Diabetes Care 2002;25:724-730) randomized 651 patients to placebo or pramlintide (60mcg three or four times daily) added to insulin for 52 weeks: HbA1c fell 0.29-0.34 percentage points more than placebo (a 0.04% reduction), alongside a significantly lower total daily and mealtime insulin dose.

A real, serious hypoglycemia warning

Symlin's label carries a boxed warning: when added to insulin, especially in type 1 diabetes, it's associated with an increased risk of severe insulin-induced hypoglycemia, particularly in the first weeks of treatment — real enough that the label requires an insulin dose reduction at initiation and recommends against use in patients with a history of severe hypoglycemia unawareness.

A real approval, modest effect size

The A1c and weight benefits pramlintide showed in its pivotal trials are real but modest — well short of the effect sizes seen with modern GLP-1 or amylin/GLP-1 combination therapies developed since. That gap is part of why it never became a blockbuster despite two decades on the market.

Discontinued, and how it compares to cagrilintide

Pramlintide (Symlin) manufacturing was discontinued in late 2025 — a real, recent, commercial exit after 20 years on market, not a safety-driven withdrawal as far as we could determine. This site's separate cagrilintide/CagriSema page covers a newer, longer-acting amylin analog that is not yet approved but has real Phase 3 data and a filed NDA. The contrast is instructive: pramlintide is proof the amylin-analog mechanism can clear FDA approval and work in real patients — it just never delivered blockbuster-scale results, and is no longer available.

References

FDA approval of Symlin (pramlintide acetate), 16 March 2005.
Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, Weyer C, Kolterman OG, "Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial," Diabetes Care 2003;26(3):784-790, PMID 12610038.
Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, Weyer C, Kolterman OG, "A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes," Diabetes Care 2002;25:724-730.